Hartley Dylan 4

What Happened
Hartley Dylan, Chief Scientific Officer of OnKure Therapeutics (OKUR), was granted a derivative award covering 110,000 shares on April 1, 2026. The Form 4 reports the acquisition price as $0.00 (i.e., a grant/award of derivative securities rather than an open‑market purchase) and no immediate cash value or sale was reported.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (appears timely).
• Reported consideration: $0.00 (derivative award).
• Shares/units granted: 110,000 (derivative).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Vesting note (Footnote F1): 1/48th of the shares subject to the option vest on May 1, 2026 and each month thereafter, subject to continued service — roughly ~2,292 shares vest per month.
• No exercise, sale, or tax‑withholding transaction reported in this filing.

Context
This was a compensation-style derivative grant (an option/award) with a four-year monthly vesting schedule. It was not an exercise or open‑market purchase, and there is no indication from this filing that any shares were sold or that the award was exercised immediately. Such grants are common for executive compensation and do not by themselves signal a buy or sell decision in the market.